Exclusive Summary

• Clear Market Demand: As a cornerstone of the WHO-recommended BPaL regimen for drug-resistant TB, Pretomanid targets hundreds of thousands of new DR-TB patients annually, representing substantial public health procurement demand.
• Breakthrough Clinical Value: It revolutionizes treatment by shortening therapy from over 20 months to just 6 months with an all-oral regimen, significantly improving patient adherence and cure rates, making it the new standard of care.
• Clear Access Advantage: Ongoing registration in high-burden countries like Indonesia and the Philippines demonstrates a quality dossier and regulatory experience, enabling partners to achieve faster market entry.
• Favorable Competitive Landscape: Although licensed generics exist, the number of quality-assured global suppliers is limited. A quality product with a cost advantage has a strong opportunity in tenders from National TB Programs (NTPs) and The Global Fund.